RIGL

Business Context and Reporting Period

Rigel Pharmaceuticals, Inc. (RIGL) is a biotechnology company focused on developing therapies for hematologic disorders and cancer. The company reported results for the quarterly period ended March 31, 2026. Its commercial portfolio includes TAVALISSE (fostamatinib) for chronic immune thrombocytopenia (ITP), REZLIDHIA (olutasidenib) for acute myeloid leukemia (AML), and GAVRETO (pralsetinib) for RET fusion-positive non-small cell lung cancer (NSCLC) and thyroid cancer.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. Debt figures reflect principal outstanding as of March 31, 2026, prior to subsequent refinancing.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 10% year-over-year, driven primarily by a 26% increase in net product sales ($54.9 million vs. $43.6 million). This was partially offset by a 60% decrease in contract revenues from collaborations ($3.9 million vs. $9.8 million), largely due to the absence of a $3.0 million milestone payment from Kissei recognized in the prior year.
• Product Performance:
  • TAVALISSE: Net sales rose 31% to $37.3 million, driven by higher volumes and price per bottle.
  • REZLIDHIA: Net sales rose 31% to $8.0 million, driven by higher volumes and price.
  • GAVRETO: Net sales rose 7% to $9.6 million.
• Expense Increases: Operating expenses increased to $46.9 million from $40.6 million. Research and Development (R&D) expenses rose 38% to $11.7 million due to clinical trial activities for the IRAK1/4 inhibitor program. Selling, General, and Administrative (SG&A) expenses increased 11% to $30.7 million due to higher commercial and personnel costs.
• Tax Provision: The provision for income taxes increased significantly to $3.0 million from $0.1 million, reflecting federal income tax expense recognized based on the utilization of deferred tax assets following the release of a valuation allowance in late 2025.

Outlook, Risks, and Unusual Items

• Collaboration Termination: On April 16, 2026, Rigel received notice from Eli Lilly to terminate their global exclusive license agreement for ocadusertib (RIPK1 inhibitor), effective June 15, 2026. Rigel does not expect to receive future milestones or royalties under this agreement but expects to regain full rights to the licensed compounds.
• Debt Refinancing (Subsequent Event): On May 5, 2026, Rigel terminated its $60 million term loan facility (with $45 million outstanding) and repaid all borrowings. Concurrently, the company entered a new revolving credit facility with a maximum capacity of $40 million (expandable to $60 million). As of the filing date, $8.0 million was drawn under the new facility.
• Regulatory Updates: The FDA approved a supplemental NDA for GAVRETO adding a boxed warning regarding serious infections. Rigel continues to discuss confirmatory trial requirements for the thyroid cancer indication with the FDA.
• Liquidity: Management believes existing cash and short-term investments are sufficient to fund operations for at least the next 12 months.
• Risks: Key risks include the potential impact of new US tariffs on patented pharmaceutical products (effective July/September 2026), reliance on third-party manufacturers, and the uncertainty of clinical trial outcomes for pipeline candidates like R289.

Investor Verification Checklist

• Debt Structure: Verify the terms and borrowing base availability of the new revolving credit facility entered into in May 2026.
• Lilly Termination Impact: Assess the financial impact of the Lilly agreement termination and the timeline for regaining rights to the ocadusertib program.
• Tariff Exposure: Evaluate the potential impact of the April 2026 US tariff proclamation on imported pharmaceutical ingredients and finished goods, specifically regarding orphan drug exemptions.
• Deferred Tax Assets: Review the sustainability of the valuation allowance release in 2025 and the company's ability to generate sufficient taxable income to utilize NOLs.
• GAVRETO Confirmatory Trials: Monitor progress on the confirmatory trial for the thyroid cancer indication to ensure continued accelerated approval.